Novonesis A/S (Novozymes A/S)
NSIS B
ISIN DK0060336014 / Valor 14371062
Novonesis A/S (Novozymes A/S)
UMushroom community rating:
About company
Novozymes A/S is a Denmark‑based industrial biotechnology company that develops, manufactures and sells enzymes and microbial solutions for industrial customers across sectors including household care, food and beverages, agriculture and animal nutrition, bioenergy, and pulp and paper. Created as a spin‑off from Novo Nordisk in 2000 and listed on Nasdaq Copenhagen, the company combines research-driven product development with global production and commercial operations to supply enzyme formulations and microorganisms used to improve process efficiency, yields and product characteristics. Its business model centers on product sales, application development and partnerships or licensing agreements with manufacturers and brands worldwide, supported by R&D and manufacturing facilities in multiple countries to tailor solutions for industrial applications.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (28.08.2026):
Novonesis A/S (Novozymes A/S) — H1 2026 results (including Q2 2026): the company delivered a strong first half with 8% organic sales growth (Q2: 9%), EUR 2,235.5m in net sales, expanded profitability (adjusted EBITDA margin 37.7%) and solid cash generation; Management raised the 2026 organic sales outlook to 7–8% and expects adjusted EBITDA margin at the higher end of 37–38%.
Sales growth
Group organic sales +8% in H1 2026 (Q2: +9%). Net sales EUR 2,235.5m in H1 (Q2 EUR 1,116.2m). Price added ~2 pp and revenue synergies ~1 pp. Exiting certain countries reduced organic growth (~1.5 pp in H1; ~1 pp expected full year).
Profitability
Adjusted EBITDA EUR 842.2m in H1 2026, margin 37.7% (Q2 margin 37.6%, adjusted EBITDA Q2 EUR 419.2m). Adjusted EBIT EUR 534.9m, margin 23.9% (Q2 adjusted EBIT margin 23.4%). Reported net profit EUR 370.8m in H1. Adjusted diluted EPS EUR 0.82 (H1), adjusted diluted EPS excl. PPA EUR 1.09.
Divisional performance
Food & Health Biosolutions: organic +9% (Food & Beverages +11%, Human Health +4%). Planetary Health Biosolutions: organic +7% (Household Care +8%, Agriculture, Energy & Tech +6%). Both developed and emerging markets grew ~8% in H1.
Cash flow & balance sheet
Free cash flow before acquisitions EUR 307.6m in H1. CAPEX-to-sales ~9.7% (planned capacity investments). Net interest-bearing debt EUR 2,737.6m; NIBD/EBITDA ~1.8x. Total equity EUR 11,154.9m, equity ratio ~67% at June 30, 2026.
Capital allocation & corporate actions
Interim dividend approved DKK 2.35 (EUR 0.31) per share. Inaugural multi‑year share buyback program approved (total EUR 1bn, to be executed 2H26–2029). Acquisition activity: Plumino (completed, EUR 41.3m net) and agreement to acquire remaining 77% of MicroBioGen announced.
Financing & other items
Issued EUR 1.7bn senior notes in March 2026; S&P rating A- (stable). Effective tax rate H1 2026 ~22.5%. Adjusted gross margin improved (adjusted gross margin H1 59.7%). Special items ~EUR 15.3m in H1 (mainly integration and ERP/combination-related costs).
Outlook (updated)
2026 guidance raised: organic sales growth now 7–8% (previously 5–7%). Adjusted EBITDA margin expected at the higher end of 37–38%. Full-year outlook factors include ~1 pp headwind from exiting countries, positive sales synergies, moderate currency effects and indicated net financial expenses EUR 80–90m and CAPEX ~12–14% of sales for the year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
27250 M
Market cap (USD)
362,683
Daily traded volume (Shares)
412.9 / 408.1
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
